Saturday 17 October 2026 Export SLN’s income statement to Excel — free account

Silence Therapeutics PLC Sponsored ADR

Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.

8.68 0.67 −7.17%

Follow SLN

Alert me

Market cap: $581.1M
P/E: 0.0×
Fwd P/E: −7.6×
Dividend yield: —
F-score: 2/9
Altman Z: −4.82
Beneish M: 45.78
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 581.10

Revenue 0.84

Net Income (59.95)

Free Cash Flow (42.26)

Net Debt (72.05)

Current Ratio 7.42

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (7.62)

P/S ratio 488.70

P/B ratio 10.66

Past 5Y EPS Growth —

This Y EPS Growth 25.40%

Next Y EPS Growth (17.33%)

Next Y revenue growth (22.48%)

Next 5Y EPS Growth (1.68%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 92.41%

10-year low 10-year high

P/B against its own 10 years 43.08%

10-year low 10-year high

EV/Sales against its own 10 years 93.48%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	69	147	85	72
Receivables	23	25	22	9
Inventory	—	—	—	—
Other	12	15	12	13
	103	187	119	94

	2023	2024	2025	Q'26
Payables	16	16	13	13
ST’ Debt	—	—	—	—
Other	7	0	0	—
	22	17	14	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	(39.74%)	(70.44%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	39.89%	31.66%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	—	—	—	—
’25	0	0	0	0	1
’24	16	1	1	25	43
’23	14	11	4	3	32
’22	8	5	4	5	22
’21	—	11	4	12	17
’20	—	2	—	8	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	2	—	—	—
’25	(12)	(22)	(11)	(17)	(62)
’24	(9)	(5)	(26)	(27)	(68)
’23	(9)	(19)	(6)	(15)	(49)
’22	(19)	(9)	(9)	(18)	(56)
’21	—	19	(8)	(14)	9
’20	—	1	—	(14)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	2	—	—	—
’25	(12)	(22)	(11)	(17)	(62)
’24	(9)	(5)	(26)	(28)	(68)
’23	(9)	(45)	(7)	(15)	(50)
’22	(19)	(9)	(9)	(19)	(57)
’21	—	19	(8)	(14)	8
’20	—	1	—	(14)	(14)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.32)	(0.26)	—	—	—
’25	(0.60)	(0.57)	(0.45)	(0.25)	(1.89)
’24	(0.05)	(0.42)	(0.75)	0.27	(0.99)
’23	(0.35)	(0.36)	(0.28)	(0.47)	(1.45)
’22	(0.35)	(0.50)	(0.25)	(0.46)	(1.56)
’21	—	(0.32)	(0.46)	(0.30)	(1.83)
’20	—	(0.17)	—	(0.36)	(1.53)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	15.00	20.50	7.80	4.55	5.81	1.97	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	22.64	35.00	24.66	18.95	27.72	8.08
People
People	Employees	—	—	—	58	74	105	122	109	116	88
	Revenue/emp, $m	0.00	0.00	—	0.01	0.10	0.16	0.18	0.29	0.37	0.01
Income, $m
Income, $m	Revenue	1	0	—	0	7	17	22	32	43	1
	Gross margin, %	59.74	(2,606.80)	0.00	0.00	31.34	39.94	37.83	59.34	72.70	61.54
	EBT	(13)	(7)	(35)	(38)	(46)	(63)	(59)	(53)	(44)	(89)
	EBT margin, %	(1,345.71)	(23,599.51)	0.00	(9,372.37)	(657.81)	(369.36)	(270.66)	(168.35)	(102.79)	(15,849.91)
	Net income	(10)	0	(31)	0	(46)	(63)	(59)	(54)	(45)	(89)
	Depreciation	0	1	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	0.04	0.00	0.00	0.02	0.26	0.58	0.67	0.85	0.94	0.01
	Earnings	(0.15)	(0.12)	(1.35)	(1.32)	(1.53)	(1.83)	(1.56)	(1.45)	(0.99)	(1.89)
	Cash flow	(0.52)	(0.59)	(1.22)	0.11	(0.51)	0.32	(1.75)	(1.33)	(1.46)	(1.32)
	Capex	0.00	0.00	0.00	0.00	(0.02)	(0.06)	(0.02)	0.00	0.00	0.00
	Free cash flow	(0.52)	(0.59)	(1.22)	0.11	(0.53)	0.25	(1.76)	(1.33)	(1.47)	(1.32)
	Book value	2.82	3.39	2.44	1.46	0.43	0.40	0.85	0.59	2.90	1.32
	Shares, m	24	28	23	25	27	30	32	37	46	47
Valuation, ×
Valuation, ×	P/E	0.00	0.00	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	—	0.00	0.00	20.33	21.85	21.74	7.36	513.72
	P/B	12.43	12.43	—	12.43	52.52	45.82	17.32	31.29	2.37	4.61
	EV/Sales	0.00	0.00	—	0.00	0.00	16.50	17.78	19.57	3.95	361.63
	EV/FCF	(291.34)	(291.34)	—	(291.34)	(108.15)	(36.56)	(6.83)	(12.51)	(2.52)	(3.24)
Cash, $m
Cash, $m	Operating cash flow	(12)	(17)	(29)	3	(14)	9	(56)	(49)	(68)	(62)
	Capex	(1)	0	0	0	(1)	(2)	(1)	0	0	0
	Free cash flow	(12)	(17)	(29)	3	(14)	8	(57)	(50)	(68)	(62)
Balance, $m
Balance, $m	Working capital	50	78	42	48	65	98	92	81	171	105
	Total debt	—	—	—	1	1	0	1	0	—	—
	Net debt	(48)	(79)	(43)	(58)	(50)	(101)	(88)	(69)	(147)	(85)
	Shareholders’ equity	67	96	57	36	12	12	27	22	134	62
Returns, %
Returns, %	ROA	(14.55)	(8.18)	(47.55)	(103.54)	(48.07)	(44.66)	(37.76)	(42.97)	(28.13)	(53.05)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(15.14)	(3.46)	(41.16)	(70.17)	(173.84)	(464.06)	(256.66)	(220.02)	(58.08)	(90.27)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZVRA Zevra Therapeutics, Inc.	$609.9M	10.5×	10.5×	+53.25% (above 0%: growing)	−88.71% (below 0%: shrinking)	+670.87% (above 0%: growing)	96.16%	42.30%	Compare
PHAT Phathom Pharmaceuticals, Inc.	$606.8M	— (loss-making)	— (loss-making)	+88.02% (above 0%: growing)	n/m	+96.86% (above 0%: growing)	79.68%	(5.34%)	Compare
OLMA Olema Pharmaceuticals, Inc.	$601.1M	— (loss-making)	—	—	n/m	−54.33% (below 0%: shrinking)	0.00%	0.00%	Compare
CRMD CorMedix Inc	$581.5M	3.0×	16.5×	+156.52% (above 0%: growing)	+13.79% (above 0%: growing)	+185.90% (above 0%: growing)	75.66%	42.10%	Compare
SLN Silence Therapeutics PLC Sponsored ADR	$581.1M	— (loss-making)	— (loss-making)	+197.18% (above 0%: growing)	n/m	+106.95% (above 0%: growing)	97.39%	0.00%
SGMT Sagimet Biosciences Inc.	$574.7M	— (loss-making)	— (loss-making)	—	n/m	−21.95% (below 0%: shrinking)	100.00%	0.00%	Compare
DBVT DBV Technologies S.A.	$572.6M	— (loss-making)	—	−53.33% (below 0%: shrinking)	n/m	−56.15% (below 0%: shrinking)	100.00%	(7,228.57%)	Compare
VALN Valneva SE Sponsored ADR	$560.4M	59.7×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)	Compare
STTK Shattuck Labs, Inc.	$555.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$578.1M	10.5×	16.5×	+21.47%	—	−10.47%	87.92%	0.00%

All 614 Biotechnology stocks →

Silence Therapeutics PLC Sponsored ADR (SLN) key facts

Concern: Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024.
Silence Therapeutics PLC Sponsored ADR (SLN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, SLN traded at $8.68, a market capitalization of $581.1 million.
Return on equity was −90.3% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −4.82 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.